glp 1 agonist contraindications GLP-1 Agonists Treatment of High-Risk Patients with
Description
& Majumdar, S
The incretin-related therapies dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) not only improve glycaemic control with a low risk of hypoglycaemia but can also have beneficial non-glycaemic effects such as avoidance of weight gain, reduced blood pressure and improvements in beta-cell function and cardiovascular risk biomarkers 1 3
No individuals developed DKA
Several case series ( Liraglutide Liraglutide is the only GLP-1RA, which has been investigated for the treatment of NAFLD
